insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

QNRX · Quoin Pharmaceuticals, Ltd. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · QNRX

1Y3Y5YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$3.43M-$2.28M$2.05M$2.37M-$1.17M$519.3K$842.8K-
SG&A$1.70M-$1.74M$1.74M$1.58M-$1.36M$1.62M$1.62M-
Total Operating Expenses$5.13M-$4.02M$3.79M$3.96M-$2.53M$2.14M$2.46M-
D&A----------
Operating Income----------
Interest Expense----------
Income Tax----------
Net Income($5.00M)-($3.95M)($3.70M)($3.81M)-($2.35M)($1.97M)($2.33M)-
EPS - Basic----------
EPS - Diluted----------

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$3.12M$3.82M$1.83M$1.67M$3.82M$3.62M$3.12M$2.85M$1.83M$2.40M
Accounts Receivable----------
Inventory----------
Accounts Payable$1.78M$1.26M$1.86M$873.7K$644.1K$905.7K$222.6K$819.7K$358.5K$526.5K
Current Assets$15.33M$20.01M$6.02M$8.48M$12.50M$14.93M$10.50M$13.22M$15.26M$11.29M
Total Assets$15.69M$20.39M$6.42M$8.91M$12.96M$15.71M$11.39M$14.05M$16.12M$12.17M
Current Liabilities$5.35M$5.55M$5.76M$4.34M$4.86M$4.18M$3.47M$3.95M$4.22M$3.58M
Long-term Debt----------
Total Liabilities$6.92M$7.27M$7.64M$6.36M$7.03M$6.50M$5.95M$6.58M$7.00M$6.51M
Stockholders' Equity$8.77M$13.12M($1.21M)$2.55M$5.93M$9.20M$5.44M$7.48M$9.13M$5.66M
Retained Earnings($75.97M)($70.97M)($66.62M)($62.67M)($58.98M)($55.17M)($52.85M)($50.50M)($48.53M)($46.20M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($4.87M)---($2.59M)---($1.43M)-
Investing Cash Flow$4.12M---$2.77M---($4.47M)-
Financing Cash Flow$56.0K---$23.0K---$5.33M-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-31.8%--61.5%-41.5%-29.4%--20.6%-14.0%-14.4%-
Return on equity-57.0%-325.1%-144.9%-64.3%--43.2%-26.4%-25.5%-
Return on invested capital----------
Liquidity
Current ratio2.873.611.041.952.573.573.023.353.613.15
Quick ratio2.873.611.041.952.573.573.023.353.613.15
Cash ratio0.580.690.320.380.790.870.900.720.430.67
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier1.791.55-5.293.492.191.712.091.881.772.15
Liabilities / Assets0.440.361.190.710.540.410.520.470.430.53
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)----------
Net income growth (YoY)-31.1%--68.0%-87.2%-63.8%---2.5%10.6%-
EPS growth (YoY)----------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)48.0%42.5%--65.9%-35.1%62.5%-0.9%-16.4%-23.5%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Quoin Pharmaceuticals against the 5 most active filers in the same SIC group.